Dishman Carbogen Amcis Limited
NSE: DCAL BSE: DCAL
Prev Close
253.2
Open Price
257.7
Volume
194,928
Today Low / High
252 / 265.85
52 WK Low / High
161.21 / 307.98
Range
243 - 269
Prev Close
250.95
Open Price
249.95
Volume
13,074
Today Low / High
249.95 / 263.45
52 WK Low / High
161.35 / 307.8
Range
243 - 268
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 256 (target range: 243 - 269), reflecting a change of 2.8 (1.10585%). On the BSE, it is listed at 255.6 (target range: 243 - 268), showing a change of 4.65 (1.85296%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Dishman Carbogen Amcis Limited Graph
Dishman Carbogen Amcis Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Dishman Carbogen Amcis Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 256.00, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 255.60 | 258.16 | 232.34 - 283.97 |
| 260.71 | 208.57 - 312.85 | ||
| 263.27 | 184.29 - 342.25 | ||
| Bearish Scenario | 255.60 | 253.04 | 227.74 - 278.35 |
| 250.49 | 200.39 - 300.59 | ||
| 247.93 | 173.55 - 322.31 |
Overview of Dishman Carbogen Amcis Limited
ISIN
INE385W01011
Industry
Biotechnology
Vol.Avg
450,451
Market Cap
40,136,448,000
Last Dividend
0
Official Website
IPO Date
2004-04-22
DCF Diff
441.85
DCF
-187
Financial Ratios Every Investor Needs
Stock Dividend of DCAL
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2019-09-12 | September 12, 19 | 0.2 | 0.2 | 2019-09-13 | 2019-10-24 | 2019-05-15 |
| 2017-02-17 | February 17, 17 | 1.2 | 1.2 | 2017-02-21 | 2017-03-01 | |
| 2016-03-17 | March 17, 16 | 1 | 2 | |||
| 2015-09-10 | September 10, 15 | 1 | 2 | |||
| 2014-08-21 | August 21, 14 | 0.6 | 1.2 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2,711.50 Cr | 501.65 Cr | 2,209.85 Cr | 0.8150 | 0.00 Cr | 0.00 Cr | 175.20 Cr | 3.24 Cr | 0.21 | 472.51 Cr | 0.0012 |
| 2024-03-31 | 2,543.62 Cr | 2,401.76 Cr | 141.86 Cr | 0.0558 | 12.98 Cr | 114.42 Cr | -47.86 Cr | -153.45 Cr | -9.79 | 307.18 Cr | -0.0603 |
| 2023-03-31 | 2,315.05 Cr | 534.21 Cr | 1,780.84 Cr | 0.7692 | 0.00 Cr | 100.34 Cr | 105.49 Cr | -29.80 Cr | -1.90 | 307.62 Cr | -0.0129 |
| 2022-03-31 | 2,140.68 Cr | 458.88 Cr | 1,681.80 Cr | 0.7856 | 13.90 Cr | 72.16 Cr | 29.85 Cr | 18.01 Cr | 1.15 | 342.56 Cr | 0.0084 |
| 2021-03-31 | 1,912.03 Cr | 484.09 Cr | 1,427.94 Cr | 0.7468 | 6.50 Cr | 63.09 Cr | -12.35 Cr | -165.13 Cr | -10.53 | 286.42 Cr | -0.0864 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 341.07 Cr | 9,999.15 Cr | 4,167.63 Cr | 5,831.5200 Cr | 2,388.95 Cr | 2,047.88 Cr | 900.24 Cr | 3,171.08 Cr | 0.00 Cr | 0.00 Cr | 71.96 Cr | 1,924.7900 Cr |
| 2024-03-31 | 264.09 Cr | 9,581.41 Cr | 3,953.91 Cr | 5,627.5000 Cr | 2,312.60 Cr | 2,048.51 Cr | 882.89 Cr | 3,236.14 Cr | 0.00 Cr | 0.00 Cr | -88.50 Cr | 2,554.7200 Cr |
| 2023-03-31 | 131.79 Cr | 9,453.50 Cr | 3,643.83 Cr | 5,809.6700 Cr | 2,208.85 Cr | 2,077.06 Cr | 803.80 Cr | 3,234.70 Cr | 429.65 Cr | 165.12 Cr | -131.56 Cr | 1,798.3900 Cr |
| 2022-03-31 | 110.24 Cr | 8,637.45 Cr | 3,088.51 Cr | 5,548.9400 Cr | 1,829.89 Cr | 1,719.65 Cr | 645.12 Cr | 2,786.88 Cr | 294.58 Cr | 126.50 Cr | 31.83 Cr | 1,419.7900 Cr |
| 2021-03-31 | 243.54 Cr | 8,366.10 Cr | 2,667.28 Cr | 5,698.8200 Cr | 1,588.85 Cr | 1,345.31 Cr | 515.65 Cr | 2,441.46 Cr | 0.00 Cr | -0.01 Cr | 55.78 Cr | 1,290.2900 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 375.2300 Cr | -192.2100 Cr | -102.0900 Cr | 158.4700 Cr | 76.9800 Cr | 341.0700 Cr | -216.7600 Cr | 19.3100 Cr | 78.7900 Cr | 0.0000 Cr | -24.4700 Cr |
| 2024-03-31 | 383.9700 Cr | -229.5200 Cr | -22.1500 Cr | 80.7200 Cr | 132.3000 Cr | 264.0900 Cr | -303.2500 Cr | -153.4500 Cr | 119.2600 Cr | 0.0000 Cr | -85.2400 Cr |
| 2023-03-31 | 265.9500 Cr | -494.0800 Cr | 249.6700 Cr | -353.7300 Cr | 21.5500 Cr | 131.7900 Cr | -619.6800 Cr | -54.5900 Cr | 134.5500 Cr | 0.0000 Cr | -158.6800 Cr |
| 2022-03-31 | 354.8500 Cr | -618.5300 Cr | 130.3700 Cr | -108.9500 Cr | -133.3000 Cr | 110.2400 Cr | -463.8000 Cr | -4.2500 Cr | 216.8200 Cr | 0.0000 Cr | -143.3000 Cr |
| 2021-03-31 | 512.6600 Cr | -380.7900 Cr | -11.0400 Cr | 146.6300 Cr | 121.6000 Cr | 243.5400 Cr | -366.0300 Cr | -65.0300 Cr | 102.4600 Cr | 0.0000 Cr | 90.9100 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 716.34 Cr | 145.91 Cr | 570.43 Cr | 0.7963 | 73.60 Cr | 43.09 Cr | 2.79 | 148.91 Cr | 0.0602 |
| 2024-12-31 | 682.34 Cr | 98.83 Cr | 583.51 Cr | 0.8552 | 68.16 Cr | 4.63 Cr | 0.30 | 147.80 Cr | 0.0068 |
| 2024-09-30 | 789.04 Cr | 190.56 Cr | 598.48 Cr | 0.7585 | 75.06 Cr | 33.09 Cr | 2.11 | 150.84 Cr | 0.0419 |
| 2024-06-30 | 523.78 Cr | 454.18 Cr | 69.60 Cr | 0.1329 | -41.62 Cr | -77.57 Cr | -4.95 | 24.96 Cr | -0.1481 |
| 2024-03-31 | 654.71 Cr | 587.91 Cr | 66.80 Cr | 0.1020 | -22.32 Cr | -69.92 Cr | -4.46 | 66.75 Cr | -0.1068 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 341.07 Cr | 25.43 Cr | 547.79 Cr | 668.77 Cr | 900.24 Cr | 2,200.42 Cr | 3,171.08 Cr | 9,999.15 Cr | 4,167.63 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 416.22 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -5,736.76 Cr |
| 2024-09-30 | 228.40 Cr | 202.09 Cr | 430.49 Cr | 710.03 Cr | 903.90 Cr | 2,144.44 Cr | 3,320.22 Cr | 10,180.45 Cr | 4,443.69 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 436.64 Cr | 0.00 Cr | 0.00 Cr | 436.64 Cr | 0.00 Cr | 0.00 Cr | -5,627.50 Cr |
| 2024-03-31 | 264.09 Cr | 167.35 Cr | 431.44 Cr | 461.11 Cr | 882.89 Cr | 1,928.19 Cr | 3,236.14 Cr | 9,581.41 Cr | 3,953.91 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 43.09 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 4.63 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 33.09 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | -77.57 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | -69.92 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2016-05-02 | May 02, 16 | 2:1 |
| 2005-10-21 | October 21, 05 | 5:1 |
Similar Stocks: Biotechnology
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Biocon Limited | BIOCON | ₹397.30 | ₹530,166,288,889.00 | ₹6,133,205.00 |
| Syngene International Limited | SYNGENE | ₹722.05 | ₹289,805,521,713.00 | ₹2,536,330.00 |
| Piramal Pharma Limited | PPLPHARMA | ₹201.37 | ₹267,670,710,034.00 | ₹4,286,230.00 |
| Concord Biotech Limited | CONCORDBIO | ₹1,824.00 | ₹190,819,948,800.00 | ₹35,048.00 |
| Blue Jet Healthcare Limited | BLUEJET | ₹796.35 | ₹138,139,187,217.00 | ₹820,514.00 |
| Jubilant Ingrevia Limited | JUBLINGREA | ₹810.60 | ₹129,113,178,600.00 | ₹229,344.00 |
| Supriya Lifescience Limited | SUPRIYA | ₹668.05 | ₹53,766,534,540.00 | ₹186,055.00 |
| Dishman Carbogen Amcis Limited | DCAL | ₹256.00 | ₹40,136,448,000.00 | ₹194,928.00 |
| Zota Health Care Limited | ZOTA | ₹1,234.85 | ₹36,383,002,975.00 | ₹56,295.00 |
Key Executives
Gender: Not Specified
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: Not Specified
Year Born:
Gender: female
Year Born: 1951
Gender: male
Year Born:
Gender: female
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1986
FAQs about Dishman Carbogen Amcis Limited
The CEO is Himani S. Dhotre.
The current price is ₹256.00.
The range is ₹161.21-307.98.
The market capitalization is ₹4,013.64 crores.
The P/E ratio is 1,219.05.
The company operates in the Healthcare sector.
Overview of Dishman Carbogen Amcis Limited (ISIN: INE385W01011) is a leading Biotechnology in India. With a market capitalization of ₹4,013.64 crores and an average daily volume of 450,451 shares, it operates in the Biotechnology. The company last declared a dividend of ₹0.